Open access · CC-BY
via OpenAlex
Osteoporosis: the current status of mesenchymal stem cell-based therapy
Jitrada Phetfong, Tanwarat Sanvoranart, Kuneerat Nartprayut, Natakarn Nimsanor, Kanokwan Seenprachawong, Virapong Prachayasittikul, Aungkura Supokawej
Cellular & Molecular Biology Letters · 2016 · ▲ 130 citations
Abstract
Osteoporosis, or bone loss, is a progressive, systemic skeletal disease that affects millions of people worldwide. Osteoporosis is generally age related, and it is underdiagnosed because it remains asymptomatic for several years until the development of fractures that confine daily life activities, particularly in elderly people. Most patients with osteoporotic fractures become bedridden and are in a life-threatening state. The consequences of fracture can be devastating, leading to substantial morbidity and mortality of the patients. The normal physiologic process of bone remodeling involves a balance between bone resorption and bone formation during early adulthood. In osteoporosis, this process becomes imbalanced, resulting in gradual losses of bone mass and density due to enhanced bone resorption and/or inadequate bone formation. Several growth factors underlying age-related osteoporosis and their signaling pathways have been identified, such as osteoprotegerin (OPG)/receptor activator of nuclear factor B (RANK)/RANK ligand (RANKL), bone morphogenetic protein (BMP), wingless-type MMTV integration site family (Wnt) proteins and signaling through parathyroid hormone receptors. In addition, the pathogenesis of osteoporosis has been connected to genetics. The current treatment of osteoporosis predominantly consists of antiresorptive and anabolic agents; however, the serious adverse effects of using these drugs are of concern. Cell-based replacement therapy via the use of mesenchymal stem cells (MSCs) may become one of the strategies for osteoporosis treatment in the future.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s11658-016-0013-1
- Canonical
- link ↗
- Fetched
- 2026-06-21 MST
Cite this
APA
Phetfong, J., Sanvoranart, T., Nartprayut, K., Nimsanor, N., Seenprachawong, K., Prachayasittikul, V., & Supokawej, A. (2016). Osteoporosis: the current status of mesenchymal stem cell-based therapy. <em>Cellular & Molecular Biology Letters</em>. https://doi.org/10.1186/s11658-016-0013-1
Vancouver
Phetfong J, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasittikul V, et al. Osteoporosis: the current status of mesenchymal stem cell-based therapy. Cellular & Molecular Biology Letters. 2016. doi:10.1186/s11658-016-0013-1.
BibTeX
@article{jitrada2016Osteop,
title = {Osteoporosis: the current status of mesenchymal stem cell-based therapy},
author = {Jitrada Phetfong and Tanwarat Sanvoranart and Kuneerat Nartprayut and Natakarn Nimsanor and Kanokwan Seenprachawong and Virapong Prachayasittikul and Aungkura Supokawej},
journal = {Cellular & Molecular Biology Letters},
year = {2016},
doi = {10.1186/s11658-016-0013-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Universidade Federal do Rio de Janeiro 2011
Open access · US-GOV
Growth Hormone Evaluation in the Elderly People
International Journal of Endocrinology 2014
Open access · CC-BY
Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Centre Hospitalier Universitaire de Nīmes 2023
Open access · US-GOV
Retrospective Study of Protocol-based Pain Management in Elderly Patients With or Without Cognitive Frailty Hospitalized at UPOG for Fracture of the Upper Extremity of the Femur in 2022
Aging Cell 2025
Open access · CC-BY
Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss
Clinical Orthopaedics and Related Research 1970
Citation only
27 The Loss of Bone with Age, Osteoporosis, and Fractures
Journal of Clinical Investigation 1983
Open access · OA